pyxis oncology is developing antibody therapeutics to promote the body's immune response to cancer, based on new insights into the tumor micro-environment.
Company profile
Ticker
PYXS
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Pyxis Securities Corporation • Apexigen, Inc. • Apexigen America Inc. ...
IRS number
831160910
PYXS stock data
Latest filings (excl ownership)
S-3
Shelf registration
27 Mar 24
8-K
Other Events
27 Mar 24
8-K
Pyxis Oncology Obtains $8 Million Payment for the Sale of Royalty Rights
27 Mar 24
10-K
2023 FY
Annual report
21 Mar 24
8-K
Pyxis Oncology Provides Corporate Update and Reports Financial Results for Fourth Quarter and Full Year 2023
21 Mar 24
8-K
Pyxis Oncology Expands Board of Directors with Appointment of Santhosh Palani, Ph.D., CFA
13 Mar 24
8-K
Pyxis Oncology Announces $50 Million Private Placement
28 Feb 24
8-K
Pyxis Oncology Announces Appointment of Ken Kobayashi, M.D., F.A.C.P as Chief Medical Officer
28 Nov 23
10-Q
2023 Q3
Quarterly report
7 Nov 23
8-K
Pyxis Oncology Announces Initiatives to Prioritize Lead ADC Program; Reports Financial Results for Third-Quarter 2023 and Provides Corporate Update
7 Nov 23
Latest ownership filings
4
Santhosh Palani
13 Mar 24
3
Santhosh Palani
13 Mar 24
SC 13G
Deep Track Capital, LP
8 Mar 24
SC 13G/A
TANG CAPITAL PARTNERS LP
14 Feb 24
SC 13G/A
BIOTECHNOLOGY VALUE FUND L P
14 Feb 24
SC 13G
Ridgeback Capital Investments L.P.
26 Jan 24
4
Ken Kobayashi
29 Dec 23
3
Ken Kobayashi
6 Dec 23
4
Pamela Ann Connealy
30 Nov 23
4
Jitendra Wadhane
17 Nov 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 16.19 mm | 16.19 mm | 16.19 mm | 16.19 mm | 16.19 mm | 16.19 mm |
Cash burn (monthly) | 3.73 mm | 15.32 mm | 8.45 mm | (no burn) | 5.86 mm | 1.18 mm |
Cash used (since last report) | 22.24 mm | 91.39 mm | 50.42 mm | n/a | 34.96 mm | 7.06 mm |
Cash remaining | -6.05 mm | -75.20 mm | -34.23 mm | n/a | -18.78 mm | 9.13 mm |
Runway (months of cash) | -1.6 | -4.9 | -4.1 | n/a | -3.2 | 7.7 |
Institutional ownership, Q4 2023
37.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 40 |
Opened positions | 7 |
Closed positions | 26 |
Increased positions | 5 |
Reduced positions | 6 |
13F shares | Current |
---|---|
Total value | 7.54 bn |
Total shares | 21.96 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
PFE Pfizer | 7.03 mm | $19.41 mm |
Lara Sullivan | 4.17 mm | $9.22 mm |
Tang Capital Partners | 3.47 mm | $0.00 |
World Investments B.V. Bayer | 2.74 mm | $30.08 mm |
Vanguard | 1.31 mm | $2.35 bn |
Standard Life Aberdeen | 708.30 k | $1.27 bn |
Vestal Point Capital | 440.00 k | $792.00 mm |
Hillhouse Capital Advisors | 382.61 k | $688.69 mm |
Renaissance Technologies | 364.15 k | $655.00 k |
Decheng Capital | 326.81 k | $588.26 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
12 Mar 24 | Santhosh Palani | Stock Option Common Stock | Grant | Acquire A | No | No | 5.7 | 69,760 | 397.63 k | 69,760 |
29 Dec 23 | Ken Kobayashi | Stock Option Common Stock | Grant | Acquire A | No | No | 1.8 | 110,878 | 199.58 k | 110,878 |
29 Dec 23 | Ken Kobayashi | Stock Option Common Stock | Grant | Acquire A | No | No | 1.8 | 443,514 | 798.33 k | 443,514 |
29 Nov 23 | Yanchik Connealy Pamela | Common Stock | Payment of exercise | Dispose F | No | No | 1.4 | 36,949 | 51.73 k | 781,583 |
News
RBC Capital Reiterates Outperform on Pyxis Oncology, Maintains $7 Price Target
22 Mar 24
Why FedEx Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
22 Mar 24
HC Wainwright & Co. Maintains Buy on Pyxis Oncology, Raises Price Target to $7
22 Mar 24
Why FactSet Research Shares Are Trading Lower By Around 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
21 Mar 24
Pyxis Oncology: Q4 Earnings Insights
21 Mar 24
Press releases
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
28 Mar 24
Pyxis Oncology Obtains $8 Million Payment for the Sale of Royalty Rights
27 Mar 24
Pyxis Oncology Provides Corporate Update and Reports Financial Results for Fourth Quarter and Full Year 2023
21 Mar 24
Pyxis Oncology Expands Board of Directors with Appointment of Santhosh Palani, Ph.D., CFA
13 Mar 24
Pyxis Oncology to Present at Leerink Global Biopharma Conference 2024
7 Mar 24